

**Curriculum Vitae for: David Sallman, M.D.**  
**Date: July 27, 2021**

**Current Position:** Assistant Member  
Department of Malignant Hematology  
H. Lee Moffitt Cancer Center and Research Institute  
12902 Magnolia Drive - CSB7 HEME  
Tampa, Florida 33612  
(813) 745-6841  
(813) 745-5639  
david.sallman@moffitt.org

**Current Academic Appointment:** Assistant Professor  
Department of Oncologic Sciences, MDC 44  
Morsani College of Medicine  
University of South Florida  
12901 Bruce B. Downs Blvd.

**Education:**  
2006 - 2010 Medical Doctor  
University of South Florida College of Medicine  
Tampa, FL

2003 - 2007 Bachelor of Science  
7-Year Honors Accelerated Medical Program  
Biomedical Sciences  
University of South Florida  
Tampa, FL

**Postgraduate Training and Fellowship Appointments:**  
2013 - 2016 Fellowship in Hematology and Medical Oncology  
University of South Florida at Moffitt Cancer Center  
Tampa, FL

2010 - 2013 Residency in Internal Medicine  
Massachusetts General Hospital  
55 Fruit St. WACC 5th Floor  
Boston, MA 02114

**Employment:**  
2016 - 2017 Clinical Instructor  
Department of Malignant Hematology  
Moffitt Cancer Center  
Tampa, FL

**Medical License:**  
2010 - Present Florida Medical License, Active

2012 - 2015                      Massachusetts Medical License, Inactive

**Board Certifications:**

2017 - Present                      Medical Oncology

2017 - Present                      Hematology

2013 - Present                      Internal Medicine

**Teaching Experience**

**Other Courses & National Symposia:**

2020                      **Speaker**, 62<sup>nd</sup> ASH Annual Meeting and Exposition, Satellite Symposia, Virtual, December 2020. Preparing for Personalized Care in Myelodysplastic Syndromes: Integrating Innovative Treatments Into a Cohesive Patient Care Model.

2020                      **Lecturer**, Aplastic Anemia & MDS International Foundation (AAMDSIF) National Patient & Family Conference, Virtual, July 2020. Moderate and High Risk MDS: A Patient Centered Approach to Diagnosis and Treatment.

2018                      **Lecturer**, You and MDS An Animated Patient's Guide to Myelodysplastic Syndromes on behalf of the MDS Foundation. [www.youandmds.com/en-mds/home](http://www.youandmds.com/en-mds/home).

2018                      **Lecturer**, 2018 ASCO and EHA MDS Update Webinar by AAMDS International Foundation.

2016–Present                      **Lecturer**, Hematology/Oncology Fellows Lecture Series, H. Lee Moffitt Cancer Center & Research Institute. Myelodysplastic Syndromes, Acute Promyelocytic Leukemia, and Acute Myeloid Leukemia

**Teaching and Training Experience:**

**Post-Doctoral Training:**

2019 - Present                      **Clinical Research Mentoring**, David Swoboda, MD (Hematology/Oncology Fellow). Clinical research projects: 1) A Phase 2 Study to Assess the Safety and Efficacy of MBG453 in Combination with Decitabine for Chronic Myelomonocytic Leukemia (accepted by Novartis) 2) Sideroblast quantification is highly predictive of TP53 mutation in MDS with excessive blasts with prognostic implications (presented as oral presentation at 2019 SOHO meeting) 3) ASXL1/SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes (presented as poster at 2019 ASH Meeting) 4) Novel therapies in myelodysplastic syndromes (Review published in Current Opinions of Hematology) 5) Mutation-Driven Therapy in MDS (Review published in Current Hematologic Malignancy Reports)

- 2018 - Present **Clinical Research Mentoring**, Todd Knepper (Personalized Medicine Specialist). Clinical research projects: 1) Increased frequency of IDH1/2 mutations in extramedullary acute myeloid leukemia.
- 2018 - Present **Clinical Research Mentoring**, Anthony Hunter, MD (Hematology/Oncology Fellow). Clinical research projects: 1) A Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab with Darbepoetin alfa in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) who have Failed Erythropoietin Stimulating Agents (ESA). 2) Baseline and Sequential Molecular Profiling Predicts Outcomes in Patients with MDS and Oligoblastic AML Treated with Hypomethylating Agents (presented as poster MDS19-0215).3) Review paper on TP53 Mutant AML. Joined faculty as MDS lead at Emory University.
- 2018 - 2020 **Clinical Research Mentoring**, Jung-Hoon Lee, MD (Internal Medicine Resident). Clinical research projects: 1) Molecular Pathogenesis of Myelodysplastic Syndromes with deletion 5q. (Accepted to European Hematology Journal). Accepted into Fellowship at Cornell University.
- 2017 - 2020 **Clinical Research Mentoring**, Seongseok Yun, MD (Hematology/Oncology Fellow). Clinical research projects: 1) Prognostic Significance of Serial Molecular Annotation in Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML) patients (presented as oral presentation at 2017 SOHO meeting, published in Leukemia).

#### **Honors and Awards, Nominations**

- 2020 Junior Faculty Research Award for Clinical Science
- 2016 Best Abstract Award Winner Moffitt Research Symposium
- 2015 Alpine Oncology Foundation Young Investigator
- 2015 Top 3 Award winner for abstract submitted to 8th International Congress on Myeloproliferative Neoplasms, Myelodysplasia and Chronic Myeloid Leukemia
- 2015 Society for Hematologic Oncology (SOHO) Travel Grant Recipient
- 2015 ASH Clinical Research Training Institute (CRTI) Participant
- 2015 ASCO Oncology Trainee Travel Award
- 2015 Best Abstract Award Winner 2015 Moffitt Research Symposium
- 2014 FLASCO Travel Grant Recipient for 2014 ASH Annual Meeting
- 2014 Society for Hematologic Oncology (SOHO) Travel Grant Recipient
- 2014 2014 AACR/ASCO Workshop Methods in Clinical Cancer Research Participant
- 2013 Society for Hematologic Oncology (SOHO) Travel Grant Recipient

2013	Resident Teaching Award – Tufts Medical School
2010	Elected to Barness/Behnke Chapter of the Gold Humanism Society
2010	Silbiger Research Scholarship Award winner for the most outstanding research commitment amongst the graduating medical class.
2010	Roy. H. Behnke, MD Award for Excellence in Internal Medicine
2010	Florida American College of Physician Award
2010	College of Medicine Academic Excellence Award
2010	Physiology Achievement Award for Outstanding performance
2009	Elected to Alpha Omega Alpha as a 3 <sup>rd</sup> Year Medical Student
2008	Outstanding Medical Student Poster Award at USF Health Research Day
2007	USF King O’ Neal Scholar Award
2006	3 <sup>rd</sup> Place Oral Presentation - USF Undergraduate Research Symposium
2006	Chemistry Honor Roll Inductee
2005	2 <sup>nd</sup> Place Oral Presentation – USF Undergraduate Research Symposium

### Research Support

#### Current

##### **External Grants:**

Account #: 84-20445-01-01  
Name and Role: **David Sallman, M.D. - PI**  
Dates: 04/2020-04/2022  
Source: Aprea Therapeutics  
Title: Aprea Central Lab Study  
% Effort: 1%  
Direct Costs: \$164,927  
Award: \$250,000

Account #: 84-19955-01-01  
Name and Role: **David Sallman, M.D. - PI**  
Dates: 02/2020 – 06/2020  
Source: Jazz  
Title: Serial MRD sequencing in AML patients treated with Vyxeos chemotherapy.  
% Effort: 1%

Direct Costs: \$79,323  
Award: \$107,879

Account #: 84-19658-01-01  
Name and Role: **David Sallman, M.D. - PI**  
Dates: 10/2019-10/2021  
Source: NHLBI R44 HL142389-01 (subcontract in collaboration with Syntrix)  
Title: A Phase 1 Open-Label Dose Escalation with Expansion Study of SX-682 in MDS patients  
% Effort: 10%  
Direct Costs: \$733,924  
Award: \$911,578

Account #: 69-18973-01-01  
Name and Role: **David Sallman, M.D. - PI**  
Dates: 10/2018 - 3/2021  
Source: Dresner Foundation  
Title: Delineation of Immune Evasive Mechanisms Driving Poor Outcome in TP53 Mutant Myelodysplastic Syndromes  
% Effort: 15%  
Direct Costs: \$108,696  
Award: \$250,000

#### **Clinical Trials:**

Name and Role: **David Sallman, M.D. - Sponsor, Investigator Initiated Trial**  
Dates: 7/2020 - Present  
Source: Precigen, Inc.  
Title: MCC 19862 A Phase 1/1b Safety Study of PRGN-3006 Adoptive Cellular Therapy in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome  
Objective: To identify and evaluate the safety and MTD of PRGN-3006 T cells in patients with relapsed or refractory AML or higher risk MDS.

Name and Role: **David Sallman, M.D. - PI, Investigator Initiated Trial**  
Dates: 6/2020 - Present  
Source: Syntrix Biosystems, Inc.  
Title: A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 in Subjects with Myelodysplastic Syndrome Who Had Disease Progression or are Intolerant to Prior Therapy.

Name and Role: **David Sallman, M.D./Eric Padron, M.D., Co-PIs, Investigator Initiated Trial**  
Dates: 12/2019 - Present  
Source: Novartis  
Title: Phase II Study to Assess the Safety and Efficacy of MBG453 in Combination with Decitabine for Chronic Myelomonocytic Leukemia.  
Objective: To determine the proportion of patients who achieve complete remission (CR) by IWG MDS/MPN criteria.

Name and Role: **David Sallman, M.D. - National PI**  
Dates: 1/2019 - Present  
Source: Aprea  
Title: A Phase III Multicenter, Randomized, Open Label Study of APR-246 in Combination with Azacitidine Versus Azacitidine Alone for the Treatment of TP53 Mutant Myelodysplastic Syndromes.  
Objective: Compare the complete response rate, defined as the proportion of patients who achieve complete remission (CR), and duration of CR with APR-246 + azacitidine treatment vs. azacitidine only.

Name and Role: **David Sallman, M.D. - PI**  
Dates: 8/2018 - Present  
Source: Amphivena  
Title: MCC 19609 A Phase 1, Multicenter, Open Label Study of AMV564, a Bispecific CD33/CD3 T-cell Engager, in Patients with Intermediate or High-Risk Myelodysplastic Syndromes  
Objective: The primary objective is to confirm the safety and tolerability of AMV564

Name and Role: **David Sallman, M.D. - PI**  
Dates: 11/2017 - Present  
Source: Forty-Seven Inc.  
Title: MCC 19322 A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in combination with Azacitidine in Patients with Hematological Malignancies.  
Objective: The primary objective is to confirm the safety and tolerability of Hu5F9-G4 monotherapy in this relapsed/refractory AML and MDS population, and of Hu5F9-G4 in combination with azacitidine in previously untreated AML and MDS. This will be measured by the objective response rate.

Name and Role: **David Sallman, M.D. - PI**  
Dates: 9/2016 - Present  
Source: Aileron Pharmaceuticals  
Title: MCC 18876 Phase 1/1b Open-Label Study for Patients taking ALRN-6924 or in combo w/Ara-C with/RR AML or MDS with TP53  
Objective: Determine the Safety and Tolerability of ALRN-6924 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome with Wild-Type TP53.

Name and Role: **David Sallman, M.D. of AML/MDS arm**  
Dates: 8/2016 - Present  
Source: Celyad Pharmaceuticals  
Title: MCC 18891 A Multinational open-label, dose escalation Phase I/II study to access the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumor types. (THINK - Therapeutic Immunotherapy with NKR-2).  
Objective: Determine the Safety and Tolerability of NKR-2 in patients with AML or MDS

Name and Role: **David Sallman, M.D. - Investigator Initiated Trial**

Dates: 3/2016 - Present  
Source: Evans MDS Consortium / Aprea  
Title: MCC 18973 A Phase 1b/2 study to Evaluate the Safety and Efficacy of APR-246 in combination with Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms opened MDS Clinical Research Symposium, currently in Phase 2.  
Objective: Safety and RP2D in Phase 1 (completed), CR by IWG 2006 is primary objective in P2.

#### **Translational Studies:**

Name and Role: **David Sallman, M.D. - PI**  
Dates: 4/2019 - Present  
Source: Jazz  
Title: Prognostic Significance of Serial Molecular Annotation in Secondary Acute Myeloid Leukemia (sAML) in patients treated with CPX-351.  
Objective: Protocol is funded and planned activation 4/2019 and activated 2/2020.

#### **Pending**

#### **External Grants:**

Account #: N/A  
Name and Role: **David Sallman, M.D. - Co-Investigator (Mark Ji, Ph.D. - PI)**  
Dates: 4/2021 - 3/2023 (proposed)  
Source: U.S. DoD Bone Marrow Failure Research Program Idea Development Award  
Title: Structure-Based Design of NLRP3 Inflammasome Inhibitors for Treatment of Myelodysplastic Syndromes  
Direct Costs: \$325,000  
Total Funds Requested: \$535,275

#### **Completed**

#### **External Grants:**

Account #: 69-18644-01-01  
Name and Role: **David Sallman, M.D. - PI**  
Dates: 5/2017 - 5/2018  
Source: MDS Foundation Young Investigator Award  
Title: Targeting TP53 Gene Mutations in Myelodysplastic Syndromes through Functional Reconstitution and Immune Activation.  
% Effort: 1%  
Direct Costs: \$22,727  
Award: \$25,000  
  
Account #: 84-18732-01-01  
Name and Role: **David Sallman, M.D. - PI**  
Dates: 9/2016 – 1/2019

Source: Celgene Pharmaceuticals  
Title: MCC 18644 Characterization of the Role of Immune Checkpoints in Myeloid Malignancies based on the Underlying Molecular Architecture to Develop Novel Targeted Therapeutic Strategies  
% Effort: 5%  
Direct Costs: \$101,692  
Award: \$174,910

#### **Internal Grants:**

Account #: 02-40000-18-17  
Name and Role: **David Sallman, M.D. - PI**  
Dates: 2/2018 - 6/2018  
Source: Cancer Biology Molecular Medicine - MCC  
Title: Delineation of Immune Evasive Mechanisms Driving Poor Outcome in TP53 Mutant Myelodysplastic Syndromes  
Direct Costs: \$20,000  
Award: \$20,000

Account #: N/A  
Name and Role: **David Sallman, M.D. - PI**  
Dates: 4/2016 - 4/2018  
Source: 2016 Moffitt Institutional Trainee Award  
Title: Characterization of the Role of Immune Checkpoints in MDS for the 5,000 award.  
% Effort: 5%  
Direct Costs: \$5,000  
Award: \$5,000

#### **Clinical Trials:**

Name and Role: **David Sallman, M.D. - PI**  
Dates: 2017 - 2020  
Source: KaloBios Pharm Inc.  
Title: MCC 18382 A Phase 1 Study of KB003 in Patients with Previously Treated Chronic Myelomonocytic Leukemia (CMML)  
Objective: The primary objective is to evaluate the safety profile and determine the recommended Phase 2 dose (RP2D) of KB003 in patients with previously treated CMML.

#### **Patents**

1. **USPTO Application #:** 15/328,235  
**Title:** Protein Phosphatase 2A Inhibitors for Treating Myelodysplastic Syndromes.  
**Inventors:** Alan F. List, David A. Sallman, John S. Kovach  
**DOP:** September 11, 2018



Service

Moffitt Cancer Center

**Administrative Appointments:**

2015 - 2016 Chief Hematology-Oncology Fellow at Moffitt Cancer Center

**Committees:**

2021 - Present **Chair**, Pharmacy and Therapeutics Committee, Monthly

2020 - Present **Member**, CRU Prioritization Taskforce, Ad Hoc

2019 - Present **Member**, MDS Committee, Monthly

2019 - Present **Member**, SRC Committee (Cypress), Monthly

2019 - Present **Author**, Myelodysplastic Syndromes (MDS) pathway, Ad Hoc

2019 - Present **Member**, ICE-T Trial Start-Up and Prioritization Council, Biweekly

2018 - Present **Member**, Fellowship Program Evaluation Committee, Yearly

2018 - Present **Member**, Fellowship Selection Committee, Yearly

2018 - Present **Member**, Pharmacy and Therapeutics Committee, Monthly

2017 - Present **Member**, PRIO Steering Committee, Monthly

2017 - 2020 **Member**, Abstract Selection Committee Scientific Symposium, Clinical and Translational Science Abstracts, Yearly

**Profession:**

2020 - Present **Member**, ENHANCE 5F9009 Steering Committee

2020 - Present **Member**, Protocol Advisory Committee for Ivosidenib in MDS

2020 - Present **Member**, National Comprehensive Cancer Network Guidelines Panel - Myelodysplastic Syndromes

2013 **Member**, Internal Medicine Selection Committee

2010 **Member**, USF College of Medicine Selection Committee

2008 - 2010 **Tutor**, Medical/Doctor of Physical Therapy Students

2009 - 2010 **Honorary President**, Project World Health - USF College of Medicine

2007 - 2008 **Vice President**, Internal Medicine Interest Group - USF College of Medicine

**National:**

- 2020                    **Session Co-Chair**, Aplastic Anemia & MDS International Foundation (AAMDSIF) 7<sup>th</sup> International Bone Marrow Failure Disease Scientific Symposium, Virtual, July 2020.
- 2019                    **Session Moderator**, Myelodysplastic Syndromes – Clinical Studies: Combination Therapies. 61<sup>st</sup> Annual American Society of Hematology Meeting & Exposition, Orange County Convention Center, Orlando, FL. December 9, 2019.
- 2018                    **Session Chair**, MDM2 Conference, St. Petersburg, FL. November 6, 2018
- 2016                    **Session Moderator**, Myelodysplastic Syndromes – Clinical Studies: Prognostic and Predictive Utility of Recurrent Somatic Mutations in Myelodysplastic Syndromes. Oral and Poster Abstracts. American Society of Hematology Annual Meeting, Manchester Grand Hyatt San Diego, California. December 3, 2016

**International:**

- 2007 - 2008            **President and Trip Organizer**, Project World Health - Dominican Republic
- 2007                    **Volunteer**, Mission trip to Mexico – constructing homes

**International Grant Reviewer:**

- 10/2017                MATWIN Project Assessment. Provides assessment, resources and networking to project leaders wishing to optimize the transfer potential of their projects. Bordeaux, France.

**Editorials and Journal Reviews:**

- 2021 - Present            **Ad Hoc Reviewer**, Cancer
- 2021 - Present            **Ad Hoc Reviewer**, Lancet Haematology
- 2021 - Present            **Ad Hoc Reviewer**, Leukemia
- 2020 - Present            **Member**, Editorial Board, Hemato
- 2020 - Present            **Ad Hoc Reviewer**, Blood Reviews
- 2019 - Present            **Ad Hoc Reviewer**, Journal of Clinical Oncology
- 2019 - Present            **Ad Hoc Reviewer**, Critical Reviews in Oncology/Hematology
- 2019 - Present            **Ad Hoc Reviewer**, Hematology, the ASH Education Program
- 2018 - Present            **Ad Hoc Reviewer**, Blood Advances

2018 - Present      **Ad Hoc Reviewer**, Springer Nature

2018 - Present      **Ad Hoc Reviewer**, Cancer Medicine

2018 - Present      **Ad Hoc Reviewer**, The American Journal of Pathology

2018 - Present      **Ad Hoc Reviewer**, Blood

2017 - Present      **Ad Hoc Reviewer**, Acta Haematologica

2017 - Present      **Ad Hoc Reviewer**, Clinical Cancer Research

2017 - Present      **Ad Hoc Reviewer**, European Medical Journal Hematology Peer Review Panel

2017 - Present      **Ad Hoc Reviewer**, Acta Haematologica, Switzerland

2016 - Present      **Ad Hoc Reviewer**, Hematology/Oncology and Stem Cell Therapy

2016 - Present      **Ad Hoc Reviewer**, Haematologica

2016 - Present      **Ad Hoc Reviewer**, New England Journal of Medicine

2016 - Present      **Ad Hoc Reviewer**, British Cancer Journal

2016 - Present      **Ad Hoc Reviewer**, BMJ Case Report

**Professional Association Memberships**

2018 - Present      **Member**, European Hematology Association

2017 - Present      **Member**, MDS Foundation

2016 - Present      **Member**, American Society of Hematology

2014 - Present      **Member**, Florida Society of Clinical Oncology

2014 - Present      **Member**, American Association for Cancer Research

2009 - Present      **Member**, Alpha Omega Alpha

2013 - 2016        **Member in Training**, American Society of Hematology

2013 - 2016        **Member in Training**, American Society of Clinical Oncology

2013 - 2016        **Fellow Representative**, Moffitt Graduate Medical Education Committee

2011 - 2013        **Associate Member**, American College of Physicians

2009 - 2010            **Member**, Medical Student Selection Committee, USF College of Medicine  
2007                    **Student Member**, A.A.C.R.  
2006 - 2010            **Student Member**, A.M.A.

**Peer-Reviewed Publications**

**Primary Research:**

1. Hunter AM, Newman H, DeZern AE, Steensma DP, Niyongere S, Roboz GJ, Mo Q, Chan O, Gerds A, **Sallman DA**, Dominguez-Viqueira W, Letson C, Balasis ME, Ball M, Kruer T, Zhang H, Lancet JE, List AF, Sekeres MA, Komrokji RS, Padron E. Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia. *Clin Cancer Res.* 2021 Jul 12;clincanres.0935.2021. doi: 10.1158/1078-0432.CCR-21-0935. Epub ahead of print. PMID: 34253584.
2. Hunter AM, Al Ali N, Mai A, Shah S, Swoboda DM, Kuykendall A, Talati C, Sweet KL, **Sallman DA**, Lancet JE, Komrokji RS, Padron E. Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy. *Leuk Res.* 2021 Jun 10;109:106640. doi: 10.1016/j.leukres.2021.106640. Epub ahead of print. PMID: 34144312.
3. Komrokji R, Al Ali N, Padron E, Lancet J, Nazha A, Steensma D, DeZern A, Roboz G, Garcia-Manero G, Sekeres MA, **Sallman D**. What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)? *Leuk Lymphoma.* 2021 Jun 11:1-6. doi: 10.1080/10428194.2021.1938028. Epub ahead of print. PMID: 34114922.
4. Komrokji RS, Volpe VO, Chan O, Al Ali NH, Swoboda DM, Kuykendall AT, Padron E, **Sallman DA**. Validation of the International Working Group Proposal for SF3B1 Mutant Myelodysplastic Syndromes. *Blood.* 2021 May 25; blood.2021010831. doi: 10.1182/blood.2021010831. Epub ahead of print. PMID: 34036300.
5. Schwabkey Z, Al Ali N, **Sallman D**, Kuykendall A, Talati C, Sweet K, Lancet J, Padron E, Komrokji R. Impact of obesity on survival of patients with myelodysplastic syndromes. *Hematology.* 2021 Dec;26(1):393-397. doi: 10.1080/16078454.2021.1929692. PMID: 34029507.
6. Hansen DK, Kim J, Thompson Z, Hussaini M, Nishihori T, Ahmad A, Elmariah H, Faramand R, Mishra A, Davila ML, Khimani F, Lazaryan A, **Sallman D**, Liu H, Perez LE, Fernandez H, Nieder ML, Lancet JE, Pidala JA, Anasetti C, Bejanyan N. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. *Transplant Cell Ther.* 2021 Mar;27(3):256.e1-256.e7. doi: 10.1016/j.jtct.2020.12.021. Epub 2021 Feb 2. PMID: 33781526.

7. Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, **Sallman D**, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganam-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. *Blood Cancer J*. 2021 Mar 6;11(3):52. doi: 10.1038/s41408-021-00446-y. PMID: 33677472.
8. Hunter AM, Komrokji RS, Yun S, Al Ali N, Chan O, Song J, Hussaini M, Talati C, Sweet KL, Lancet JE, Padron E, List AF, **Sallman DA**. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. *Blood Adv*. 2021 Feb 23;5(4):1017-1028. doi: 10.1182/bloodadvances.2020003508. PMID: 33591325; PMCID: PMC7903224.
9. Cluzeau T, Sebert M, Rahmé R, Cuzzubbo S, Lehmann-Che J, Madelaine I, Peterlin P, Bève B, Attalah H, Chermat F, Miekoutima E, Rauzy OB, Recher C, Stamatoullas A, Willems L, Raffoux E, Berthon C, Quesnel B, Loschi M, Carpentier AF, **Sallman DA**, Komrokji R, Walter-Petrich A, Chevret S, Ades L, Fenaux P. Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM). *J Clin Oncol*. 2021 Feb 18;JCO2002342. doi: 10.1200/JCO.20.02342. Epub ahead of print. PMID: 33600210.
10. Richardson DR, Swoboda DM, Moore DT, Johnson SM, Chan O, Galeotti J, Esparza S, Hussaini MO, Van Deventer H, Foster MC, Coombs CC, Montgomery ND, **Sallman DA (Co-Last Author)**, Zeidner JF. Genomic Characteristics and Prognostic Significance of Co-mutated ASXL1/SRSF2 Acute Myeloid Leukemia. *Am J Hematol*. 2021 Jan 27. doi: 10.1002/ajh.26110. Epub ahead of print. PMID: 33502020.
11. **Sallman DA**, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbel G, Attar EC, Kantarjian HM, Lancet JE, Fenaux P, List AF, Komrokji RS. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. *J Clin Oncol*. 2021 Jan 15;JCO2002341. doi: 10.1200/JCO.20.02341. Epub ahead of print. PMID: 33449813.
12. Komrokji RS, Al Ali NH, **Sallman D**, Padron E, DeZern AE, Barnard J, Roboz GJ, Garcia-Manero G, List A, Steensma DP, Sekeres MA. Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium. *Cancer Med*. 2020 Dec 22. doi: 10.1002/cam4.3608. Epub ahead of print. PMID: 33350168.
13. Swoboda DM, Ali NA, Chan O, Padron E, Kuykendall AT, Song J, Hussaini M, Talati C, Sweet K, Lancet JE, **Sallman DA**, Komrokji RS. PTPN11 mutations are associated with poor outcomes across myeloid malignancies. *Leukemia*. 2020 Nov 1. doi: 10.1038/s41375-020-01083-3. Epub ahead of print. PMID: 33132383.

14. Schwabkey ZI, Al Ali N, Chan O, **Sallman DA**, Padron E, Kuykendall AT, Talati C, Sweet K, Lancet JE, Komrokji RS. Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase Karyotype. *Clin Lymphoma Myeloma Leuk*. 2020 Aug 18;S2152-2650(20)30427-4. doi: 10.1016/j.clml.2020.08.012. Epub ahead of print. PMID: 33093008.
15. **Sallman DA**. The Problem of TP53-Mutant MDS/AML. *Clin Lymphoma Myeloma Leuk*. 2020 Sep;20 Suppl 1: S65-S66. doi: 10.1016/S2152-2650(20)30465-1. PMID: 32862873.
16. Patnaik MM, **Sallman DA (Co-First Author)**, Mangaonkar AA, Heuer R, Hirvela J, Zblewski D, Al-Kali A, Binder M, Balasis ME, Newman H, Letson C, Kruer TL, Gangat N, Komrokji RS, Tefferi A, Lo A, Shih T, Durrant C, List AF, Padron E. Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. *Blood*. 2020 Aug 13;136(7):909-913. doi: 10.1182/blood.2019004352. PMID: 32294158.
17. Yun S, Geyer SM, Komrokji RS, Al Ali NH, Song J, Hussaini M, Sweet KL, Lancet JE, List AF, Padron E, **Sallman DA**. Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). *Leukemia*. 2020 Jul 29. doi: 10.1038/s41375-020-0997-4. Epub ahead of print. PMID: 32728186.
18. Castillo-Tokumori F, Talati C, Al Ali N, **Sallman D**, Yun S, Sweet K, Padron E, Lancet J, Komrokji R, Kuykendall AT. Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis. *Clin Lymphoma Myeloma Leuk*. 2020 Jul 16;S2152-2650(20)30340-2. doi: 10.1016/j.clml.2020.07.006. Epub ahead of print. PMID: 32778513.
19. **Sallman DA**, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou HA, Eksioglu EA, Sullivan A, Warren S, MacBeth KJ, Meggendorfer M, Haferlach T, Boettcher S, Ebert BL, Al Ali NH, Lancet JE, Cleveland JL, Padron E, List AF. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. *Blood*. 2020 Dec 10;136(24):2812-2823. doi: 10.1182/blood.2020006158. PMID: 32730593.
20. Ball BJ, Famulare CA, Stein EM, Tallman MS, Derkach A, Roshal M, Gill SI, Manning BM, Koprivnikar J, McCloskey J, Testi R, Prebet T, Al Ali NH, Padron E, **Sallman DA**, Komrokji RS, Goldberg AD. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. *Blood Adv*. 2020 Jul 14;4(13):2866-2870. doi: 10.1182/bloodadvances.2020001482. PMID: 32589727; PMCID: PMC7362378.
21. Komrokji RS, Ali NA, **Sallman D**, Padron E, Lancet J, Sokol L, Varnadoe C, Burnette PK, List A. Characterization of myelodysplastic syndromes (MDS) with T-cell large granular lymphocyte proliferations (LGL). *Leukemia*. 2020 Jun 21. doi: 10.1038/s41375-020-0928-4. Epub ahead of print. PMID: 32565544.
22. **Sallman DA**. To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia. *Haematologica*. 2020 Jun;105(6):1470-1472. doi: 10.3324/haematol.2020.249060. PMID: 32482751; PMCID: PMC7271586.
23. Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boulwood J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, Haferlach T, Heuser M, Jansen JH, Komrokji RS,

- Maciejewski JP, Walter MJ, Fontenay M, Garcia-Manero G, Graubert TA, Karsan A, Meggendorfer M, Pellagatti A, **Sallman DA**, Savona MR, Sekeres M, Steensma DP, Tauro S, Thol F, Vyas P, Van de Loosdrecht AA, Haase DT, Tuechler H, Greenberg PL, Ogawa S, Hellstrom-Lindberg ES, Cazzola M. SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). *Blood*. 2020 Apr 29. pii: blood.2020004850. doi: 10.1182/blood.2020004850. [Epub ahead of print] PubMed PMID: 32347921.
24. Talati C, Goldberg AD, Przespolewski A, Chan O, Ali NA, Kim J, Famulare C, **Sallman D**, Padron E, Kuykendall A, Lancet JE, Wang E, Tallman MS, Komrokji R, Sweet K. Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. *Leuk Res*. 2020 Jun;93:106367. doi: 10.1016/j.leukres.2020.106367. Epub 2020 May 1. PMID: 32408060.
25. Duong VH, Al Ali N, Zhang L, Padron E, **Sallman D**, Lancet JE, List AF, Komrokji RS. A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure. *Leuk Lymphoma*. 2020 Apr 19:1-7. doi: 10.1080/10428194.2020.1751841. [Epub ahead of print] PubMed PMID: 32306798.
26. **Sallman DA**, Barnard J, Al Ali NH, Garcia-Manero G, Sekeres MA, DeZern A, Steensma DP, Roboz G, Jabbour E, Maciejewski JP, Pierce S, Padron E, Lancet JE, Kantarjian H, List AF, Komrokji RS. Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. *Clin Lymphoma Myeloma Leuk*. 2020 Mar 20. pii: S2152-2650(20)30138-5. doi: 10.1016/j.clml.2020.03.005. [Epub ahead of print] PubMed PMID: 32303488.
27. Patnaik MM, **Sallman DA**, Mangaonkar A, Heuer R, Hirvela J, Zblewski D, Al-Kali A, Binder M, Balasis ME, Newman H, Letson C, Kruer TL, Gangat N, Komrokji RS, Tefferi A, Lo A, Shih T, Durrant C, List AF, Padron E. Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia (CMML). *Blood*. 2020 Apr 15. pii: blood.2019004352. doi: 10.1182/blood.2019004352. [Epub ahead of print] PubMed PMID: 32294158.
28. Melody M, Kuykendall A, **Sallman D**, Al Ali N, Zhang L, Talati C, Padron E, Sweet K, Extermann M, List A, Lancet J, Komrokji R. Defining Acute Myeloid Leukemia Ontogeny in Older Patients. *Clin Lymphoma Myeloma Leuk*. 2019 Nov 9. pii: S2152-2650(19)32104-4. doi: 10.1016/j.clml.2019.11.007. [Epub ahead of print] PubMed PMID: 32139296.
29. Nguyen L, Zhang X, Roberts E, Yun S, McGraw K, Abraham I, Song J, Braswell D, Qin D, **Sallman DA**, Lancet JE, List AF, Moscinski LC, Padron E, Zhang L. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated RUNX1 versus acute myeloid leukemia with myelodysplasia-related changes with mutated RUNX1. *Leuk Lymphoma*. 2020 Feb 24:1-11. doi: 10.1080/10428194.2020.1723016. [Epub ahead of print] PubMed PMID: 32091281.
30. Melody M, Al Ali N, Zhang L, Ramadan H, Padron E, **Sallman D**, Sweet K, Lancet J, List A, Bennett JM, Komrokji R. Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes. *Clin Lymphoma Myeloma Leuk*. 2020 Jan 14. pii: S2152-2650(20)30039-2. doi: 10.1016/j.clml.2020.01.003. [Epub ahead of print] PubMed PMID: 32044274.
31. Badar T, Szabo A, **Sallman D**, Komrokji R, Lancet J, Padron E, Song J, Hussaini MO.

Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. *Leuk Lymphoma*. 2020 Feb 4:1-10. doi: 10.1080/10428194.2020.1719089. [Epub ahead of print] PubMed PMID: 32013644.

32. Calleja A, Yun S, Moreilhon C, Karsenti JM, Gastaud L, Mannone L, Komrokji R, Al Ali N, Dadone-Montaudie B, Robert G, Auberger P, Raynaud S, **Sallman DA (Co-Senior Author)**, Cluzeau T. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment. *Eur J Haematol*. 2020 Jan 28. doi: 10.1111/ejh.13390. [Epub ahead of print] PubMed PMID: 31990086.
33. Swoboda DM, Gesiotto Q, **Sallman DA**. Novel therapies in myelodysplastic syndromes. *Curr Opin Hematol*. 2020 Mar;27(2):58-65. doi: 10.1097/MOH.0000000000000562. PubMed PMID: 31972686.
34. Badaat I, Mirza S, Padron E, **Sallman D**, Komrokji R, Song J, Hussaini MO. Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome. *J Clin Pathol*. 2019 Nov 26. pii:jclinpath-2019-206132. doi: 10.1136/jclinpath-2019-206132. [Epub ahead of print] PubMed PMID: 31771970.
35. Yun S, Sharma R, Chan O, Vincelette ND, **Sallman DA**, Sweet K, Padron E, Komrokji R, Lancet JE, Abraham I, Moscinski LC, Cleveland JL, List AF, Zhang L. Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). *Leuk Res*. 2019 Sep;84:106194. doi: 10.1016/j.leukres.2019.106194. Epub 2019 Jul 18. PubMed PMID: 31357093.
36. McGraw KL, Cheng CH, Chen YA, Hou HA, Nilsson B, Genovese G, Cluzeau T, Pellagatti A, Przychodzen BP, Mallo M, Arenillas L, Mohamedali A, Adès L, **Sallman DA**, Padron E, Sokol L, Moreilhon C, Raynaud S, Tien HF, Boultonwood J, Ebert BL, Sole F, Fenaux P, Mufti GJ, Maciejewski JP, Kanetsky PA, List AF. Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis. *Blood Adv*. 2019 Nov 26;3(22):3579-3589. doi:10.1182/bloodadvances.2019000922. PubMed PMID: 31738830; PubMed Central PMCID: PMC6880887.
37. Sweet K, Komrokji R, Padron E, Cubitt CL, Turner JG, Zhou J, List AF, **Sallman DA**, Dawson JL, Sullivan DM, Chavez J, Shah BD, Lancet JE. Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia. *Clin Cancer Res*. 2019 Oct 21. doi: 10.1158/1078-0432.CCR-19-2169. [Epub ahead of print] PubMed PMID: 31636097.
38. Kuykendall AT, Talati C, Padron E, Sweet K, Lancet JE, List AF, **Sallman D**, Komrokji RS. Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis. *Am J Hematol*. 2019 Aug 23. doi:10.1002/ajh.25625. [Epub ahead of print] PubMed PMID: 31444809.
39. Cheng P, Eksioglu EA, Chen X, Kandell W, Le Trinh T, Cen L, Qi J, **Sallman DA**, Zhang Y, Tu N, Adams WA, Zhang C, Liu J, Cleveland JL, List AF, Wei S. S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes. *Leukemia*. 2019 Aug;33(8):2034-2046. doi: 10.1038/s41375-019-0397-9. Epub 2019 Feb 8. PubMed PMID: 30737486; PubMed Central PMCID: PMC6687540.
40. Haase D, Stevenson KE, Neuberger D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-



- Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, **Sallman D**, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultonwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. *Leukemia*. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11. PubMed PMID: 30635634; PubMed Central PMCID: PMC6609480.
41. Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, **Sallman DA**, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J, Litvin R, Famulare CA, Patel MA, Maloy M, Castro-Malaspina H, Giralt SA, Weinberg RS, Mascarenhas JO, Mesa R, Rondelli D, Dueck AC, Levine RL, Gupta V, Hoffman R, Rampal RK. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis. *Biol Blood Marrow Transplant*. 2019 Jun;25(6):1142-1151. doi: 10.1016/j.bbmt.2019.01.002. Epub 2019 Jan 6. PubMed PMID: 30625392.
42. **Sallman DA**, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH, Zhang L, Nardelli LA, Padron E, List AF, Lancet JE. A phase 2 trial of the oral smoothed inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). *Leuk Res*. 2019 Mar 30;81:56-61. doi: 10.1016/j.leukres.2019.03.008. [Epub ahead of print] PubMed PMID: 31030089.
43. Chung J, **Sallman DA**, Padron E. TP53 and therapy-related myeloid neoplasms. *Best Pract Res Clin Haematol*. 2019 Mar;32(1):98-103. doi: 10.1016/j.beha.2019.02.009. Epub 2019 Feb 19. Review. PubMed PMID: 30927980.
44. Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, **Sallman D**, Lancet JE, Tinsley S, Nardelli LA, Pinilla-Ibarz J, Epling-Burnette PK, List AF. A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes. *Clin Lymphoma Myeloma Leuk*. 2019 Mar;19(3):157-161. doi: 10.1016/j.clml.2018.12.005. Epub 2018 Dec 20. PubMed PMID: 30713125.
45. Cheng P, Eksioğlu EA, Chen X, Kandell W, Le Trinh T, Cen L, Qi J, **Sallman DA**, Zhang Y, Tu N, Adams WA, Zhang C, Liu J, Cleveland JL, List AF, Wei S. S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes. *Leukemia*. 2019 Feb 8. doi: 10.1038/s41375-019-0397-9. [Epub ahead of print] PubMed PMID: 30737486.
46. McGraw KL, Nguyen J, Al Ali NH, Komrokji RS, **Sallman D**, Zhang X, Song J, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes. *Br J Haematol*. 2019 Feb;184(3):450-455. doi: 10.1111/bjh.15099. Epub 2018 Jan 23. PubMed PMID: 29359794.
47. Komrokji RS, Al Ali NH, Padron E, Cogle C, Tinsley S, **Sallman D**, Lancet JE, List AF. Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial. *Clin Lymphoma Myeloma Leuk*. 2019 Jan 2. pii: S2152-2650(18)31193-5. doi: 10.1016/j.clml.2018.12.014. [Epub ahead of print] PubMed

PMID: 30852241.

48. Kuykendall AT, Talati C, Padron E, Sweet K, **Sallman D**, List AF, Lancet JE, Komrokji RS. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. *Am J Hematol*. 2018 Nov 2. doi: 10.1002/ajh.25335. [Epub ahead of print] PubMed PMID: 30390311.
49. Benton CB, Khan M, **Sallman D**, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. *Am J Hematol*. 2018 Oct;93(10):1245-1253. doi: 10.1002/ajh.25234. Epub 2018 Sep 26. PubMed PMID: 30051599.
50. **Sallman DA**, Brayer J, Sagatys EM, Lonez C, Breman E, Agaugué S, Verma B, Gilham DE, Lehmann FF, Davila ML. NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient. *Haematologica*. 2018 Sep;103(9):e424-e426. doi: 10.3324/haematol.2017.186742. Epub 2018 Apr 27. PubMed PMID: 29703727; PubMed Central PMCID: PMC6119132.
51. Basiorka AA, McGraw KL, Abbas-Aghababazadeh F, McLemore AF, Vincelette ND, Ward GA, Eksioglu EA, **Sallman DA**, Ali NA, Padron E, Pinilla-Ibarz J, Komrokji R, Masala E, Santini V, Kosmider O, Fontenay M, Fenaux P, Sokol L, Wei S, Fridley B, List AF. Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. *Lancet Haematol*. 2018 Sep;5(9):e393-e402. doi: 10.1016/S2352-3026(18)30109-1. Epub 2018 Jul 30. PubMed PMID: 30072146.
52. Duchmann M, Yalniz FF, Sanna A, **Sallman D**, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Adès L, Fontenay M, Rampal R, Padron E, Droin N, Preudhomme C, Santini V, Patnaik MM, Fenaux P, Solary E, Itzykson R. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. *EBioMedicine*. 2018 May; 31:174-181. doi: 10.1016/j.ebiom.2018.04.018. Epub 2018 Apr 25. PubMed PMID: 29728305; PubMed Central PMCID: PMC6013781.
53. Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, **Sallman DA**, Lancet JE, List AF, Zuckerman KS, Komrokji RS. Between a rock and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. *Ann Hematol*. 2018 Mar;97(3):435-441. doi: 10.1007/s00277-017-3194-4. Epub 2017 Nov 30. PubMed PMID: 29189896.
54. Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, **Sallman DA**, Lancet JE, List AF, Zuckerman KS, Komrokji RS. The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval. *Clin Lymphoma Myeloma Leuk*. 2017 Dec;17(12):e45-e53. doi: 10.1016/j.clml.2017.08.002. Epub 2017 Aug 5. PubMed PMID: 28869184.
55. **Sallman DA**, Komrokji R, Cluzeau T, Vaupel C, Al Ali NH, Lancet J, Hall J, List A, Padron E, Song J. ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS. *Blood Cancer J*. 2017 Nov 27;7(12):633. doi: 10.1038/s41408-017-0004-0. PubMed PMID: 29176559; PubMed Central PMCID: PMC5802523.
56. Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, Catala G, Machiels JH,

- Piette F, Brayer JB, **Sallman DA**, Kerre T, Odunsi K, Davila ML, Gilham DE, Lehmann FF. Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. *BMJ Open*. 2017 Nov 12;7(11):e017075. doi: 10.1136/bmjopen-2017-017075. PubMed PMID: 29133316; PubMed Central PMCID: PMC5695348.
57. Kharfan-Dabaja MA, Komrokji RS, Zhang Q, Kumar A, Tsalatsanis A, Perkins J, Nishihori T, Field T, Al Ali N, Mishra A, **Sallman D**, Salem KZ, Zhang L, Moscinski L, Fernandez HF, Lancet J, List A, Anasetti C, Padron E. TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. *Clin Lymphoma Myeloma Leuk*. 2017 Nov;17(11):753-758. doi: 10.1016/j.clml.2017.06.003. Epub 2017 Jun 16. PubMed PMID: 28687222; PubMed Central PMCID: PMC5675815.
58. **Sallman DA**, Padron E. Myelodysplasia in younger adults: outlier or unique molecular entity? *Haematologica*. 2017 Jun;102(6):967-968. doi: 10.3324/haematol.2017.165993. PubMed PMID: 28566339; PubMed Central PMCID: PMC5451326.
59. Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, **Sallman DA**, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. *Lancet Oncol*. 2017 Jan;18(1):112-121. doi: 10.1016/S1470-2045(16)30627-1. Epub 2016 Dec 4. PubMed PMID: 27927582.
60. Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, **Sallman DA**, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. *Blood*. 2016 Dec 22;128(25):2960-2975. doi: 10.1182/blood-2016-07-730556. Epub 2016 Oct 13. PubMed PMID: 27737891; PubMed Central PMCID: PMC5179338.
61. Coombs CC, **Sallman DA**, Devlin SM, Dixit S, Mohanty A, Knapp K, Al Ali NH, Lancet JE, List AF, Komrokji RS, Padron E, Arcila ME, Klimek VM, van den Brink MR, Tallman MS, Levine RL, Rampal RK, Rapaport F. Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. *Haematologica*. 2016 Nov;101(11):e457-e460. Epub 2016 Jul 14. PubMed PMID: 27418649; PubMed Central PMCID: PMC5394875.
62. Clara JA, **Sallman DA**, Padron E. Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. *Cancer Biol Med*. 2016 Sep;13(3):360-372. PubMed PMID: 27807503; PubMed Central PMCID: PMC5069836.
63. McGraw KL, Nguyen J, Komrokji RS, **Sallman D**, Al Ali NH, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. *Haematologica*. 2016 Aug;101(8):e320-3. doi: 10.3324/haematol.2016.143214. Epub 2016 Apr 14. PubMed PMID: 27081179; PubMed Central PMCID: PMC4967580.
64. **Sallman DA**, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, Al Ali NH, Lancet J,

McGinniss MJ, Nahas S, Smith AE, Kulasekararaj A, Mufti G, List A, Hall J, Padron E. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. *Leukemia*. 2016 Mar;30(3):666-73. doi:10.1038/leu.2015.304. Epub 2015 Oct 30. PubMed PMID: 26514544.

65. McGraw KL, Cluzeau T, **Sallman DA**, Basiorka AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M, Sokol L, Solé F, Maciejewski J, List AF. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. *Oncotarget*. 2015 Oct 27;6(33):34437-45. doi: 10.18632/oncotarget.5255. PubMed PMID: 26416416; PubMed Central PMCID: PMC4741464.
66. Zhong B, **Sallman DA**, Gilvary DL, Pernazza D, Sahakian E, Fritz D, Cheng JQ, Trougakos I, Wei S, Djeu JY. Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells. *Mol Cancer Ther*. 2010 Jun;9(6):1831-41. doi: 10.1158/1535-7163.MCT-090880. Epub 2010 May 25. PubMed PMID: 20501799; PubMed Central PMCID: PMC3874868.
67. Chen X, Bai F, Sokol L, Zhou J, Ren A, Painter JS, Liu J, **Sallman DA**, Chen YA, Yoder JA, Djeu JY, Loughran TP, Epling-Burnette PK, Wei S. A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia. *Blood*. 2009;113(14):3226-34. Epub 2008/12/17. doi: 10.1182/blood-2008-07-168245. PubMed PMID: 19075187; PMCID: PMC2665892.
68. **Sallman DA**, Chen X, Zhong B, Gilvary DL, Zhou J, Wei S, Djeu JY. Clusterin mediates TRAIL resistance in prostate tumor cells. *Mol Cancer Ther*. 2007 Nov;6(11):2938-47. PubMed PMID: 18025278.

#### Review Articles:

1. Swoboda DM, **Sallman DA**. The promise of macrophage directed checkpoint inhibitors in myeloid malignancies. *Best Pract Res Clin Haematol*. 2020 Dec;33(4):101221. doi: 10.1016/j.beha.2020.101221. Epub 2020 Nov 6. PMID: 33279177.
2. Hunter AM, **Sallman DA**. Targeting TP53 Mutations in Myelodysplastic Syndromes. *Hematol Oncol Clin North Am*. 2020 Apr;34(2):421-440. doi: 10.1016/j.hoc.2019.11.004. Epub 2019 Dec 12. Review. PubMed PMID: 32089220.
3. Swoboda DM, **Sallman DA**. Mutation-Driven Therapy in MDS. *Curr Hematol Malig Rep*. 2019 Nov 23. doi: 10.1007/s11899-019-00554-4. [Epub ahead of print] Review. PubMed PMID: 31760573.
4. Hunter AM, **Sallman DA**. Current status and new treatment approaches in TP53 mutated AML. *Best Pract Res Clin Haematol*. 2019 Jun;32(2):134-144. doi: 10.1016/j.beha.2019.05.004. Epub 2019 May 11. Review. PubMed PMID: 31203995.
5. **Sallman DA**, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. *Blood*. 2019 Mar 7;133(10):1039-1048. doi: 10.1182/blood-2018-10-844654. Epub 2019 Jan 22. Review. PubMed PMID: 30670444.

6. Lee JH, List A, **Sallman DA**. Molecular pathogenesis of myelodysplastic syndromes with deletion 5q. *Eur J Haematol*. 2019 Mar;102(3):203-209. doi: 10.1111/ejh.13207. Epub 2019 Jan 16. Review. PubMed PMID: 30578738.
7. **Sallman, DA**. Targeting TP53 Mutations in Myelodysplastic Syndromes. *The Hematologist*. Nov/Dec 2018;15(6). No PMID.
8. Talati C, **Sallman D**, List AF. SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q. *Clin Lymphoma Myeloma Leuk*. 2018 Oct;18(10):629-635. doi: 10.1016/j.clml.2018.07.293. Epub 2018 Jul 30. Review. PubMed PMID: 30097406.
9. **Sallman DA**, Tanaka TN, List A, Bejar R. SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes. *Clin Lymphoma Myeloma Leuk*. 2017 Oct;17(10):613-620. doi: 10.1016/j.clml.2017.09.018. Epub 2017 Sep 25. Review. PubMed PMID: 29025689.
10. Zhang L, McGraw KL, **Sallman DA**, List AF. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications. *Leuk Lymphoma*. 2017 Aug;58(8):1777-1790. doi: 10.1080/10428194.2016.1266625. Epub 2016 Dec 14. Review. PubMed PMID: 27967292.
11. **Sallman DA**, Davila ML. Is Disease-Specific Immunotherapy a Potential Reality for MDS? *Clin Lymphoma Myeloma Leuk*. 2017 Jul;17S:S26-S30. doi: 10.1016/j.clml.2017.03.292. Review. PubMed PMID: 28760299.
12. Talati C, **Sallman D**, List A. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond. *Semin Hematol*. 2017 Jul;54(3):159-166. doi: 10.1053/j.seminhematol.2017.06.003. Epub 2017 Jun 22. Review. PubMed PMID: 28958290.
13. **Sallman DA**, Lancet JE. What are the most promising new agents in acute myeloid leukemia? *Curr Opin Hematol*. 2017 Mar;24(2):99-107. doi: 10.1097/MOH.0000000000000319. Review. PubMed PMID: 28030373.
14. **Sallman DA**, Padron E. Integrating mutation variant allele frequency into clinical practice in myeloid malignancies. *Hematol Oncol Stem Cell Ther*. 2016 Sep;9(3):89-95. doi: 10.1016/j.hemonc.2016.04.003. Epub 2016 May 11. Review. PubMed PMID: 27187622.
15. **Sallman DA**, Cluzeau T, Basiorka AA, List A. Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype. *Front Oncol*. 2016 Jun 16;6:151. doi: 10.3389/fonc.2016.00151. eCollection 2016. Review. PubMed PMID: 27379212; PubMed Central PMCID: PMC4909736.
16. Clara JA, **Sallman DA**, Padron E. Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. *Cancer biology & medicine*. 2016;13(3):360-72. Epub 2016/11/04. doi: 10.20892/j.issn.2095-3941.2016.0043. PubMed PMID: 27807503; PMCID: PMC5069836.

17. **Sallman DA**, Padron E. Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular Characterization. Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl: S50-5. doi: 10.1016/j.clml.2015.03.005. Review. PubMed PMID: 26297278.
18. **Sallman DA**, Wei S, List A. PP2A: The Achilles Heal in MDS with 5q Deletion. Front Oncol. 2014 Sep 23;4:264. doi: 10.3389/fonc.2014.00264. eCollection 2014. Review. PubMed PMID: 25295231; PubMed Central PMCID: PMC4172014.

### **Books**

1. **Sallman D**, Chaudbury A, Nguyen J, Zhang. Handbook of Hematologic Malignancies, 2<sup>nd</sup> Ed. Springer Publishing Company, 2020.
2. **Sallman D**, Chaudhury A, Nguyen J, Zhang L, List A. Handbook of Hematologic Malignancies. Springer Publishing Company, 2017.
2. **Sallman DA**. Co-editor of the MGH Housestaff Manual, 2013-2014 Edition.

### **Book Chapters**

1. Padron E, **Sallman DA**, Mughal T, List AF. Chapter 12: Myelodysplastic syndromes/myeloproliferative neoplasms. Accepted for Publication by Oxford University Press (Publishing date 11/2020). Oxford Specialist Handbook: Myeloproliferative Neoplasms.
2. **Sallman DA**, List A. The role of innate immunity in MDS Pathogenesis. Hemisphere Educational Updates in Hematology Book. 2019; Vol (Sx).
3. Padron E, **Sallman D**, Mughal T, and List A. MDS-MPN Overlap Syndromes. Oxford Specialist Handbook: Myeloproliferative Neoplasms. Oxford University Press 2016.
4. **Sallman D**, Djeu J. Immunological Sculpting Natural Killer Cell Receptors and Ligands. Cancer Immunotherapy: Immune Suppression and Tumor Growth. Edited by: George C. Prendergast and Elizabeth M. Jaffee 2013 Elsevier Inc. ISBN 9780123942968

### **Oral Presentations/Poster Presentations/Scientific Abstracts**

#### **Oral Presentations:**

1. **Sallman DA**, Asch AS, Kambhampati DS, Al Malki MM, Zeidner JF, Donnellan W, Lee DJ, Vyas P, Jeyakumar D, Mannis GN, Tanaka TN, Chai-Ho W, Larson RA, Whiteley AR, Marcucci G, Komrokji RS, Garcia-Manero G, Van Elk J, Lin M, Maute R, Volkmer J, Takimoto CH, Chao MP, Daver N. The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results. ASH Meeting Abstracts #330. Dec 2020. Presenting Author.
2. Radakovich N, **Sallman DA**, Buckstein RJ, Brunner AM, Mukherjee S, Komrokji RS, Al Ali N, Shreve J, Roupail Y, Kerr CM, Guan Y, Kuzmanovic T, Hasipek M, Jha BK, Maciejewski JP,

Sekeres MA, Nazha. Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS). ASH Meeting Abstracts #655. Dec 2020.

3. **Sallman DA**. The first-in-class anti-CD47 antibody magrolimab combined with azacytidine is well-tolerated and effective in AML patients: phase 1b results. EHA 2020, Virtual, June 2020. Presenting Author.
4. **Sallman DA**. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase 1b results. ASCO 2020, Virtual, May 2020. Presenting Author.
5. **Sallman DA**, DeZern A, Garcia-Manero G, Steensma D, Roboz G, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw K, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali N, Padron E, Korbel G, Attar E, Kantarjian H, Lancet JE, Fenaux P, List AE, Komrokji RS. Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). Blood 2019; 134 (Supplement\_1): 676. doi: <https://doi.org/10.1182/blood-2019-131055>. Presenting Author.
6. **Sallman DA**, Asch A, Malki M, Lee D, Donnellan W, Marcucci G, Kambhampati S, Daver N, Garcia-Manero G, Komrokji RS, Van Elk J, Lin M, Volkmer J, Takimoto C, Chao M, Vyas P. The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results. Blood 2019; 134 (Supplement\_1): 569. doi: <https://doi.org/10.1182/blood-2019-126271>. Presenting Author.
7. Swoboda D, Lee JH, Chan O, Komrokji RN, Al Ali N, Padron E, List AF, Hussaini M, Song J, **Sallman DA**. Ring Sideroblast Quantification is Highly Predictive of TP53 Mutation in MDS with Excessive Blasts with Prognostic Implications. Abstract # MDS-300. Houston, TX. September 2019.
8. **Sallman DA**. The First-in-Class Anti-CD47 Antibody HU5F9-G4 is Active and well tolerated alone or in combination with azacitidine in AML and MDS patients: Initial Phase 1B results. Abstract # S878. EHA 24, Amsterdam, the Netherlands. June 2019. Presenting Author.
9. **Sallman DA**, Kerre T, Poire X, Havelange V, Lewalle P, Davila M, Wang E, Dekker D, Snykers S, Sotiropoulou P, Breman E, Braun N, Lonz C, Verma B, Lehmann F, Brayer J. Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy. Blood 2018 132:902
10. McGraw K, Cheng C, Chen Y, Hou H, Genovese G, Cluzeau T, Pellagatti A, Przychodzen B, Mallo M, Leonor A, Mohamedali A, Ades L, **Sallman DA**, Padron E, Sokol L, Moreilhon C, Raynaud S, Nilsson B, Tien H, Boulwood J, Ebert B, Sole F, Fenauxm P, Mufti G, Maciejewski J, Kanetsky P, List AF. SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition. Blood 2018 132:107 - Presenting Author.

11. **Sallman DA**, Dezern A, Sweet K, Steensma D, Cluzeau T, Sekeres M, Garcia-Manero G, Roboz G, McLemore K, Puskas J, Zhang L, Bhagat C, Graber A, Al Ali N, Padron E, Tell R, Lancet JE, Fenauz P, List AF, Komrokji RS. Phase 1B/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDA) and Acute Myeloid Leukemia (AML). Abstract #: S1558. EHA 23, Stockholm, Sweden. June 2018.
12. **Sallman DA**, McLemore A, Komrokji RS, McGraw K, Geyer SM, Eksioglu E, Al Ali N, Lancet JE, Wei S S, Padron E and List AF. Immune Checkpoint Profiling of TP53 Mutant and Wild-Type Myeloid Malignancies: TP53 Mutations Direct Immune Tolerance Via an Immunosuppressive Phenotype. Blood 2017 130:423
13. Duchmann M , Yalniz F, Sanna A, **Sallman DA**, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Ades L, Fontenay M, Rampal RK, Padron E, Droin N, Preudhomme C, Santini V, Patnaik MM, Fenauz P, Solary E, and Itzykson R. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents. A Report on 183 Patient. Blood 2017 130:159
14. Prognostic Significance of Serial Molecular Annotation in Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML). Plenary Session, Oral Presentation. SOHO 2017 Annual Meeting. Houston, Texas. September 13-16, 2017.
15. Prognostic Significance of Serial Molecular Annotation Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML). Oral Presentation. The 14<sup>th</sup> International Symposium on Myelodysplastic Syndromes. Valencia, Spain. May 3 thru May 6, 2017.
16. Inferior Outcomes in CMML without Negative Impact in MDS, Poster Presentation. SOHO Annual Meeting on ASXL1 Frameshift Mutations Drive. Westin Galleria, Houston, Texas. September 2016
17. Impact of Hypomethylating Agent Therapy in Myelodysplastic Syndromes with Chromosome 3 Abnormalities. Oral Presentation at 2016 Moffitt Research Symposium, Moffitt Cancer Center, Tampa, FL. May 2016
18. Phase 1b/2 Trial of Azacitidine with APR-246 in TP53 Mutated Myeloid Neoplasms. MDS Clinical Research Consortium, Edward P. Evans Foundation. Rockport, Maryland March 2016
19. Bejar R, Papaemmanuil E, Haferlach T, Garcia-Manero G, Maciejewski JP, Sekeres MA, Walter MJ, Graubert TA, Cazzola M, Malcovati L, Ogawa S, Fenauz P, Hellstrom-Lindberg E, Kern W, Boulwood J, Pellagatti A, Bowen D, Tauro S, Groves MJ, Vyas P, Quek L, Nazha A, Thol F, Heuser M, Shih LY, Padron E, **Sallman D**, Komrokji RS, List AF AF, Santini V, Fontenay M, Peter J Campbell PJ, Tüchler H, Stevenson K, Neuberg DS, Peter Greenberg P and Ebert BL. Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. ASH Annual Abstracts. Dec 2015.
20. Impact of Mutation Variant Allele Frequency on Phenotype, Outcomes, and Patient Management in Myelodysplastic Syndrome. Oral presentation - 8<sup>th</sup> International Congress on Myeloproliferative Neoplasms, Myelodysplasia and Chronic Myeloid Leukemia. Rockport, Maryland. November 2015



21. Impact of Mutation Variant Allele Frequency on Phenotype, Outcomes, and Patient Management in Myelodysplastic Syndromes/Poster. 25<sup>th</sup> Annual Mayo Clinic Hematology/Oncology Reviews. Ritz-Carlton, Amelia Island, Florida. July 2015
22. Impact of Mutation Variant Allele Frequency on Phenotype, Outcomes, and Patient Management in Myelodysplastic Syndromes/ Poster. SOHO 2015 Annual Meeting, Hilton Americas, Houston, TX. September 2015
23. Variant Allele Frequency (VAF) Influences the Phenotypic Penetrance of TP53 Mutations in Myeloid Malignancies. Moffitt Research Symposium on Malignancies, Moffitt Cancer Center, Tampa, FL, May 2015. Presenting Author.
24. Influence of variant allele frequency (VAF) on the phenotypic penetrance of TP53 mutations in myeloid malignancies. ASCO Annual Meeting, Chicago, IL, 2015. Presenting Author.
25. Chromosomal 3 Abnormalities in Myelodysplastic Syndromes: Implications on Prognostic Value and Response to Treatment. ASH Annual Abstracts. December 2014
26. 4<sup>th</sup> Annual USF Undergraduate Research Symposium, Tampa FL, 2006. Presenting Author.

**Poster Presentations:**

1. **Sallman DA**, Elmariah H, Sweet KL, Talati C, Mishra A, Kelley LL, Lankford A, Chan T, Shah RR, Padron E, Komrokji RS, Lancet JE, Sabzevari H, Davila ML, Bejanyan N. A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome. ASH Meeting Abstracts #2864. Dec 2020. Presenting Author.
2. **Sallman DA**, Al-Homsi AS, Davila M, Kerre T, Moors I, Poire X, Havelange V, Lewalle P, Pollyea DA, Wang ES, Blum W, Demoulin B, Sotiropoulou PA, Alcantar-Orozco E, Breman E, Dheur MS, Braun N, Lonez C, Gilham DE, Flament A, Lehmann FF. Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. ASH Meeting Abstracts #993. Dec 2020. Presenting Author.
3. Roboz GJ, DeAngelo DJ, **Sallman DA**, Guzman ML, Desai P, Kantarjian HM, Konopleva M, Bejanyan N, Elmariah H, Esteva FJ, Garton A, Backhouse K, Galetto R, Brownstein C, Pemmaraju N. Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia. ASH Meeting Abstracts #1039. Dec 2020.
4. **Sallman DA**, Brayer J, Poire X, Havelange V, Awada A, Lewalle P, Odunsi K, Wang ES, Lonez C, Lequertier T, Alcantar-Orozco E, Braun N, Flament A, Moors I, Kerre T. Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory

Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. *Blood* 2019; 134 (Supplement\_1): 3826. doi: <https://doi.org/10.1182/blood-2019-128020>. Presenting Author.

5. Swoboda D, Lee JH, Chan O, Komrokji RS, Al Ali N, Padron E, List AF, Hussaini MO, Song J, **Sallman DA**. Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts. *Blood* 2019; 134 (Supplement\_1): 4244. doi: <https://doi.org/10.1182/blood-2019-124772>.
6. **Sallman DA**, Davila M, Brayer J, Kerre T, Poire X, Havelange V, Lewalle P, Al-Homsi S, Purev E, Wang ES, Sotiropoulou P, Braun N, Lonz C, Flament A. Updated results from Phase I trials assessing a NKG2D Car T-Cell approach in relapse/refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome patients. Abstract # PS1212. EHA 24, Amsterdam, the Netherlands. June 2019. Presenting Author.
7. **Sallman DA**. The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results. Abstract #7009. ASCO Annual Meeting, Chicago, IL. June 2019. Presenting Author.
8. **Sallman DA**, Borate U, Cull E, Donnellan W, Komrokji RS, Steidl U, Corvez M, Payton M, Annis D, Pinchasik D, AivadoM, Verma A. Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type. *Blood* 2018 132:4066. Presenting Author.
9. **Sallman DA**, DeZern A, Steensma D, Sweet K, Cluzeau T, Sekeres M, Garcia-Manero G, Roboz G, McLemore A, McGraw K, Puskas J, Zhang L, Bhagat C, Yao J, Al Ali N, Padron E, Tell R, Lancet JE, Fenaux P, List AF, Komrokji RS. Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). *Blood* 2018 132:3091. Presenting Author.
10. **Sallman DA**, Al Ali N, Yun S, Padron E, Song J, Hussaini M, Talati C, Sweet K, Lancet JE, List AF, Komrokji RS. Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival. *Blood* 2018 132:1817.
11. Knepper TC, Deutsche YE, Bhagat CK, Watts JM, Bradley TJ, Samra W, Hussaini MO, Sweet KL, Talati C, Padron E, Komrokji RS, Lancet JE, **Sallman DA**. Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia. *Blood* 2018 132:1524.
12. Melody M, **Sallman DA**, Al Ali N, Ramadan H, Zhang L, Padron E, Sweet K, Extermann M, List AF, Lancet JE and Komrokji RS. Defining Acute Myeloid Leukemia Ontogeny in Older Patients. *Blood* 2017 130:2594.
13. Patnaik MM, **Sallman DA**, Sekeres MA, Luger S, Bejar R, Hobbs GS, DeZern AE, Bolognese J, Traynor M, Mishra V, Wages D, Gualberto A, Scholz C, and Padron E. Preliminary Results from an Open-Label, Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML). *Blood* 2017 130:2963.

14. Drusbosky LM, Komrokji SE, Al Ali N, Singh NK, Kumar C, Vasista S, Sahu D, Naga G, Dattatraya P, Abbasi T, Vali S, **Sallman DA**, Komrokji RS, and Cogle CR. Computational Biology Approach to Predict Hypomethylating Agent (HMA) Response Using Genomic and Clinical Characteristics in Myelodysplastic Syndromes (MDS). *Blood* 2017 130:2954.
15. MGH Scientific Advisory Committee Poster Session, 2012. Presenting Author.
16. ACP National Meeting, Poster Presentation Toronto, Canada, 2010. Presenting Author.
17. USF Health Research Day – Poster Presentation, Tampa, FL, 2008. Presenting Author.
18. 1<sup>st</sup> Annual Undergraduate Student Caucus at AACR National Meeting Washington D.C., 2006. Presenting Author.
19. 3<sup>rd</sup> Annual USF Undergraduate Research Symposium, Tampa, FL, 2005. Presenting Author.

### **Invited Seminars**

1. 3<sup>rd</sup> International Workshop on Acute Leukemias (iwAL) 2021. Virtual, April 2021. Anti-CD47 and Panel Discussion.
2. MPN-MDS-AML U.S. Focus Meeting, MD Education. Virtual, April 2021. The most difficult to treat: Hope for TP53-mutated and KMT2A-rearranged AML? and Panel Discussion.
3. Hematologic Malignancy Symposium, Baylor College of Medicine. Virtual, March 2021. Panel discussion - Prime time - post inductionAML maintenance, HMA vs targeted therapy or both?
4. Hematologic Malignancy Symposium, Baylor College of Medicine. Virtual, March 2021. P53 directed myeloid therapies.
5. 4<sup>th</sup> International Symposium in Hematologic Oncology. Virtual, March 2021. The mother of unmet need. What are the most promising strategies for high-risk TP53 mutant myeloid neoplasms: from target agents to immune checkpoint inhibitors.
6. 11<sup>th</sup> Annual Spanish MDS Meeting, Spanish Group of Myelodysplastic Syndromes (GESMD). Virtual, March 2021. Inflammatory Signaling in MDS.
7. Blood and Marrow Transplant and Cellular Immunology Grand Rounds, Moffitt Cancer Center. Virtual, February 2021. A New Frontier: Novel Cellular Therapies for Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients.
8. International Workshop on Acute Leukemias (iwAL) Post-62<sup>nd</sup> ASH 2020 Program. Virtual, January 2021. The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results.
9. Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020). Virtual, November 2020. Novel Immunotherapies in Myeloid Malignancies.

10. 2<sup>nd</sup> International Workshop on CAR-T (*iwCAR-T*), Virtual, October 2020. NKG2D and anti-CD33 CART.
11. Hemedicus Acute Leukemia Forum (ALF) 2020, Virtual, October 2020. Can one overcome TP53 mutations in Acute Myeloid Leukemia.
12. The Society of Hematologic Oncology (SOHO) 2020 Annual Meeting, Virtual, September 2020. The Problem of Mutant P53 AML.
13. The Society of Hematologic Oncology (SOHO) 2020 Annual Meeting, Virtual, September 2020. Targeting p53 in MDS.
14. Aplastic Anemia & MDS International Foundation (AAMDSIF) 7<sup>th</sup> International Bone Marrow Failure Disease Scientific Symposium, Virtual, July 2020. Novel strategies for TP53 mutated AML/MDS.
15. Oregon Health & Science University Center for Hematologic Malignancies Grand Rounds, Virtual, June 2020. Novel Therapies in the Management of TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia.
16. Texas MD Anderson Emil J Freireich Hematology Grand Rounds, Virtual, June 2020. Novel Therapies in the Management of TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia.
17. University of Miami Sylvester Comprehensive Cancer Center 2<sup>nd</sup> Biennial Leukemia Symposium, Miami, FL. February 2020. TP53-Targeted Therapy in MDS/AML.
18. 16<sup>th</sup> Annual Clinical Breakthroughs in Hematologic Malignancies, Lake Buena Vista, FL, January 2020. Debate: Should MRD Positivity guide therapy in non M3 AML?
19. The Boston Society Acute Myeloid Leukemia Medicinal Symposium, Cambridge, MA, October 2019. State of the Art Research and Treatment Updates: Advances in the Management of TP53 Mutant Acute Myeloid Leukemia.
20. The Society of Hematologic Oncology (SOHO) 2019 Annual Meeting, Houston, TX. September 2019. Case Presentation: Managing TP53-Mutant MDS.
21. Edwards Comprehensive Cancer Center Oncology Grand Rounds, Huntington, WV, April 2019. Incorporation of Next Generation Sequencing Data in the Management of MDS/AML with Focus on TP53 Mutant Disease.
22. 15<sup>th</sup> Annual Clinical Breakthroughs in Hematologic Malignancies, Lake Buena Vista, FL. January 2019. Initial Management of High-Molecular Risk MDS Patients.
23. 9<sup>th</sup> Annual MDM2 Workshop, Saint Pete Beach, FL, November 2018. Evolving clinical data on APR-246 in TP53 mutant myelodysplastic syndrome and acute myeloid leukemia.
24. ION Immuno-Oncology Meeting, Charlotte, NC, September 2018. Keynote Address on Appropriate Use of Genomic Testing in Oncology Today.

25. 14<sup>th</sup> Annual Clinical Breakthroughs in Hematologic Malignancies. Lake Buena Vista, FL. January 2018. Integrating Genomics into Treatment Algorithms for AML.
26. Vinmec Research Institute of Stem Cell and Gene Technology. Hanoi, Vietnam. October 2017. Is Disease-Specific Immunotherapy a Potential Reality for MDS and AML?
27. Florida Society of Clinical Oncology Fall Session, Orlando, FL, October 2017. Precision Medicine and Molecular Testing.
28. Imedex guest faculty for CME certified conference, Philadelphia, PA, August 2017. Myelodysplastic syndromes: Genomic Landscape. U.S. Focus on MPN & MDS.
29. 13th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies, Lake Buena Vista, FL. January 2017. Treating the Elderly Patient with AML.
30. 10th CML & MPN Post ASH workshop. Oakland, FL, December 2015. Clinical Impact of Mutations in Myeloid Malignancies.
31. 10th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies, Lake Buena Vista, FL, January 2014. Case Presentation for MDS.
32. Keynote speaker for SPARK Day at H. Lee Moffitt Cancer Center and Research Institute. Boston, MA 2012.